Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: 10x Genomics (TXG), Arrowhead Pharmaceuticals (ARWR) and Legend Biotech (LEGN)

Tipranks - Tipranks - Tue Apr 21, 5:14AM CDT

Analysts have been eager to weigh in on the Healthcare sector with new ratings on 10x Genomics (TXG), Arrowhead Pharmaceuticals (ARWR) and Legend Biotech (LEGN).

Claim 30% Off TipRanks

10x Genomics (TXG)

In a report released today, Michael Ryskin from Bank of America Securities reiterated a Hold rating on 10x Genomics, with a price target of $30.00. The company’s shares closed last Friday at $26.08.

According to TipRanks.com, Ryskin is a 3-star analyst with an average return of 1.5% and a 49.5% success rate. Ryskin covers the Healthcare sector, focusing on stocks such as West Pharmaceutical Services, Caris Life Sciences, Inc., and Tempus AI, Inc. Class A. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for 10x Genomics with a $21.77 average price target, a -16.5% downside from current levels. In a report issued on April 6, TipRanks – xAI also reiterated a Hold rating on the stock with a $23.00 price target.

See the top stocks recommended by analysts >>

Arrowhead Pharmaceuticals (ARWR)

In a report released today, Jason Gerberry from Bank of America Securities maintained a Buy rating on Arrowhead Pharmaceuticals, with a price target of $93.00. The company’s shares closed last Friday at $69.51.

According to TipRanks.com, Gerberry is a 5-star analyst with an average return of 19.8% and a 61.9% success rate. Gerberry covers the Healthcare sector, focusing on stocks such as Harmony Biosciences Holdings, Mineralys Therapeutics, Inc., and Amylyx Pharmaceuticals Inc. ;'>

Arrowhead Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $93.67, a 34.3% upside from current levels. In a report issued on April 7, H.C. Wainwright also reiterated a Buy rating on the stock with a $100.00 price target.

Legend Biotech (LEGN)

According to TipRanks.com, Darout is a 5-star analyst with an average return of 28.5% and a 58.6% success rate. Darout covers the Healthcare sector, focusing on stocks such as Monopar Therapeutics Inc, Protagonist Therapeutics, and Iovance Biotherapeutics. ;'>

Currently, the analyst consensus on Legend Biotech is a Strong Buy with an average price target of $53.73, a 153.3% upside from current levels. In a report issued on April 7, RBC Capital also maintained a Buy rating on the stock with a $62.00 price target.

Read More on TXG:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).